Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate, ciltacabtagene autoleucel, or cilta-cel, is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.

Legend Biotech Corporation

RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech on April 7 and set a price target of $62.00. The company’s shares clo...

RBC Capital Sticks to Their Buy Rating for Legend Biotech (LEGN)

Legend Biotech Corporation (($LEGN)) has held its Q4 earnings call. Read on for the main highlights of the call. Legend Biotech’s latest earnings c...

Legend Biotech Earnings Call Highlights CARVYKTI Momentum

In a report released yesterday, Rishi Jaluria from RBC Capital maintained a Buy rating on Legend Biotech, with a price target of $62.00. The compan...

RBC Capital Reaffirms Their Buy Rating on Legend Biotech (LEGN)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Legend Biotech, with a price target of $78.00. Tenthoff c...

Current Quarter	$-0.02	Next Quarter	$0.05
Current Year	$0.34	Next Year	$1.87
QoQ Growth	+350.0%	YoY Growth	+450.0%
3Y EPS CAGR	+29.5%	Target Price	$60.63
Consensus	Buy	Upside	+231.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LEGN	$18.30	0.00%	2.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LEGN	$18.30	0%	2.27M
3
4
5
6

LEGN

LEGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Legend Biotech Corporation Data in Excel

Get Legend Biotech Corporation Data in Excel